Emotional Brain B.V.
Records under this name other than patents Emotional Brain B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,227,453 | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,653,051 | Use of 3-alpha-androstanediol in combination with a PDE5 inhibitor, in the treatment of sexual dysfunction Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,966,933 | Drug Delivery System Formerly held In force · High confidence | In force | High confidence | |
| US 9,763,884 | Drug Delivery System Formerly held In force · High confidence | In force | High confidence | |
| US 8,669,242 | Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction Formerly held Lapsed on the fee record Ended Mar 11, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 11, 2026 | USPTO record |
| US 8,648,060 | Use of 3-alpha-androstanediol in combination with a 5-HT1a agonist, in the treatment of sexual dysfunction Formerly held Lapsed on the fee record Ended Feb 11, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 11, 2026 | USPTO record |
| US 8,575,139 | Use of testosterone and a 5-HT1a agonist in the treatment of sexual dysfunction Formerly held Lapsed on the fee record Ended Nov 5, 2025 · USPTO record | Lapsed on the fee record | Ended Nov 5, 2025 | USPTO record |
| US 9,737,548 | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction Formerly held Lapsed on the fee record Ended Aug 22, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 22, 2025 | USPTO record |
| US 9,192,669 | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction Formerly held Term ended Term ended Jun 30, 2025 · USPTO record | Term ended | Term ended Jun 30, 2025 | USPTO record |
| US 9,700,566 | Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction Formerly held Term ended Ended no later than May 11, 2025 · USPTO record | Term ended | Ended no later than May 11, 2025 | USPTO record |